Literature DB >> 27488560

Expanding the phenotype of hawkinsinuria: new insights from response to N-acetyl-L-cysteine.

Natalia Gomez-Ospina1, Anna I Scott2, Gia J Oh3, Donald Potter3, Veena V Goel3, Lauren Destino3, Nancy Baugh3, Gregory M Enns3, Anna-Kaisa Niemi3, Tina M Cowan3,2.   

Abstract

Hawkinsinuria is a rare disorder of tyrosine metabolism that can manifest with metabolic acidosis and growth arrest around the time of weaning off breast milk, typically followed by spontaneous resolution of symptoms around 1 year of age. The urinary metabolites hawkinsin, quinolacetic acid, and pyroglutamic acid can aid in identifying this condition, although their relationship to the clinical manifestations is not known. Herein we describe clinical and laboratory findings in two fraternal twins with hawkinsinuria who presented with failure to thrive and metabolic acidosis. Close clinical follow-up and laboratory testing revealed previously unrecognized hypoglycemia, hypophosphatemia, combined hyperlipidemia, and anemia, along with the characteristic urinary metabolites, including massive pyroglutamic aciduria. Treatment with N-acetyl-L-cysteine (NAC) restored normal growth and normalized or improved most biochemical parameters. The dramatic response to NAC therapy supports the idea that glutathione depletion plays a key role in the pathogenesis of hawkinsinuria.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27488560     DOI: 10.1007/s10545-016-9963-8

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  17 in total

1.  A new form of prolonged transient tyrosinemia presenting with severe metabolic acidosis.

Authors:  D M Danks; P Tippett; J Rogers
Journal:  Acta Paediatr Scand       Date:  1975-03

2.  Hawkinsinuria--identification of quinolacetic acid and pyroglutamic acid during an acidotic phase.

Authors:  C H Hocart; B Halpern; L A Hick; C O Wong
Journal:  J Chromatogr       Date:  1983-07-08

3.  Excretion of cis- and trans-4-hydroxycyclohexylacetic acid in addition to hawkinsin in a family with a postulated defect of 4-hydroxyphenylpyruvate dioxygenase.

Authors:  A Niederwieser; S K Wadman; D M Danks
Journal:  Clin Chim Acta       Date:  1978-12-01       Impact factor: 3.786

4.  Hawkinsinuria: a dominantly inherited defect of tyrosine metabolism with severe effects in infancy.

Authors:  B Wilcken; J W Hammond; N Howard; T Bohane; C Hocart; B Halpern
Journal:  N Engl J Med       Date:  1981-10-08       Impact factor: 91.245

5.  Long-term follow up of a new case of hawkinsinuria.

Authors:  W Lehnert; W Stögmann; U Engelke; R A Wevers; G B van den Berg
Journal:  Eur J Pediatr       Date:  1999-07       Impact factor: 3.183

6.  Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene (HPD) in patients with tyrosinemia type III.

Authors:  U Rüetschi; R Cerone; C Pérez-Cerda; M C Schiaffino; S Standing; M Ugarte; E Holme
Journal:  Hum Genet       Date:  2000-06       Impact factor: 4.132

Review 7.  Assessment of the clinical use of intravenous and oral N-acetylcysteine in the treatment of acute acetaminophen poisoning in children: a retrospective review.

Authors:  Martha G Blackford; Thomas Felter; M David Gothard; Michael D Reed
Journal:  Clin Ther       Date:  2011-09-03       Impact factor: 3.393

8.  High anion gap metabolic acidosis secondary to pyroglutamic aciduria (5-oxoprolinuria): association with prescription drugs and malnutrition.

Authors:  G Brooker; J Jeffery; T Nataraj; M Sair; R Ayling
Journal:  Ann Clin Biochem       Date:  2007-07       Impact factor: 2.057

9.  New tyrosine metabolites in humans: hawkinsin and cis- and trans-4-hydroxycyclohexylacetic acids. Unusual adsorption of deuterated and non-deuterated hawkinsin during gas chromatography.

Authors:  A Niederwieser; A Matasović; F Neuheiser; E Wetzel
Journal:  J Chromatogr       Date:  1978-09-01

10.  A new sulfur amino acid, named hawkinsin, identified in a baby with transient tyrosinemia and her mother.

Authors:  A Niederwieser; A Matasovic; P Tippett; D M Danks
Journal:  Clin Chim Acta       Date:  1977-05-02       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.